Sucrose-formulated octocog alfa: a review of its use in patients with haemophilia A.

Drugs
James E Frampton, Antona J Wagstaff

Abstract

Sucrose-formulated octocog alfa (Kogenate Bayer, Kogenate FS, Helixate FS, Helixate nexgen) is a full-length recombinant human coagulation factor VIII (FVIII) product that is purified and formulated without the addition of human serum albumin and is stabilized with sucrose. The purification process of this formulation includes a solvent/detergent viral inactivation step. Sucrose-formulated octocog alfa is approved in the EU and US for the treatment of bleeding in patients with haemophilia A (congenital FVIII deficiency). Additionally, it is approved in the EU for the prophylaxis of bleeding in patients with haemophilia A and as a continuous infusion treatment in patients undergoing major surgery. Sucrose-formulated octocog alfa is effective and well tolerated as a FVIII replacement therapy in patients with haemophilia A, including those with severe disease undergoing major surgery. The therapeutic profile of this sucrose-formulated product cannot be compared with that of other octocog alfa or moroctocog alfa products because of a lack of head-to-head comparative studies. Pathogen transmission has not been reported with use of sucrose-formulated octocog alfa. Available data indicate that sucrose-formulated octocog alfa is an app...Continue Reading

References

Dec 21, 2000·Haemophilia : the Official Journal of the World Federation of Hemophilia·I ScharrerE Kellermann
Jun 16, 2001·Haemophilia : the Official Journal of the World Federation of Hemophilia·A YoshiokaUNKNOWN Coganate FS Study Group
Jun 9, 2001·The New England Journal of Medicine·P M Mannucci, E G Tuddenham
Sep 8, 2001·Seminars in Thrombosis and Hemostasis·B G Boedeker
Apr 30, 2002·The Annals of Pharmacotherapy·Joan M Stachnik, Michael P Gabay
May 16, 2002·Haemophilia : the Official Journal of the World Federation of Hemophilia·A Batorova, U Martinowitz
May 16, 2002·Haemophilia : the Official Journal of the World Federation of Hemophilia·A VillarF Hernandez-Navarro
Mar 18, 2003·Seminars in Thrombosis and Hemostasis·Stefan Lethagen
Jun 28, 2003·Haemophilia : the Official Journal of the World Federation of Hemophilia·J WightC Knight
Mar 11, 2004·Blood Reviews·Manuel D Carcao, Louis Aledort
May 14, 2004·Journal of Thrombosis and Haemostasis : JTH·P LarsonE Burmeister Getz
May 25, 2004·Expert Opinion on Pharmacotherapy·Natalya AnanyevaEvgueni Saenko
Aug 5, 2006·Current Opinion in Hematology·Angelika Batorova, Uri Martinowitz
Aug 5, 2006·Current Opinion in Hematology·Jenny GoudemandThierry Calvez
Oct 21, 2006·Current Opinion in Hematology·Shannon L Meeks, Cassandra D Josephson
Nov 7, 2006·Haemophilia : the Official Journal of the World Federation of Hemophilia·K Peerlinck, C Hermans
May 5, 2007·Expert Opinion on Biological Therapy·Yesim Dargaud, Claude Negrier
May 12, 2007·American Journal of Hematology·Massimo Franchini
Aug 10, 2007·The New England Journal of Medicine·Marilyn J Manco-JohnsonBruce L Evatt
Jan 16, 2008·Haemophilia : the Official Journal of the World Federation of Hemophilia·M RubingerUNKNOWN Association of Hemophilia Clinic Directors of Canada
Jan 25, 2008·Thrombosis and Haemostasis·Roberto MussoUNKNOWN KOGENATE Bayer European PMS Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.